A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine
Trial details
- Registry ID
- NCT05679908
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as intranasal oxytocin
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic MigraineNCT05679908 | Tonix Pharmaceuticals, Inc. | Phase 2 | Completed | 2023-10-08Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |